title: Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
abstract: Silymarin, derived from the milk thistle plant Silybum marianum and widely used for self-treatment of liver diseases, is composed of six major flavonolignans including silybin A and silybin B, which are the predominant flavonolignans quantified in human plasma. The single- and multiple-dose pharmacokinetics of silymarin flavonolignans were examined in patients with nonalcoholic fatty liver disease (NAFLD) or hepatitis C virus (HCV) to determine whether the disposition of silymarin and therefore its potential efficacy vary among liver disease populations. Cohorts of eight subjects with noncirrhotic liver disease were randomized 3:1 to oral silymarin or placebo (280 or 560 mg) every 8 h for 7 days. Forty-eight-hour blood sampling was conducted after the first and final doses. In general, plasma concentrations of silybin A and silybin B were higher, whereas concentrations of conjugates were lower in NAFLD compared with HCV. After adjustment of the area under plasma concentration-time curve from 0 to 8 h (AUC(0-8 h)) for weight and dose, only silybin B and silybin B conjugates differed significantly between disease types. For NAFLD, the adjusted mean AUC(0-8 h) was higher for silybin B (p < 0.05) but lower for silybin B conjugates (p < 0.05) compared with that for HCV. At the 280-mg dose, steady-state plasma concentrations of silybin B conjugates for NAFLD subjects were characterized by 46% lower AUC(0-8 h) (p < 0.05) and 42% lower C(max) (p < 0.05) compared with HCV subjects. Evidence of enterohepatic cycling of flavonolignans was only observed in NAFLD subjects. In summary, the efficacy of silymarin may be more readily observed in NAFLD patients because of their higher flavonolignan plasma concentrations and more extensive enterohepatic cycling compared with those in HCV patients.
authors.affiliation: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599-7360, USA.
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Schrieber
authors.forename: Roy L
authors.initials: RL
authors.lastname: Hawke
authors.forename: Zhiming
authors.initials: Z
authors.lastname: Wen
authors.forename: Philip C
authors.initials: PC
authors.lastname: Smith
authors.forename: K Rajender
authors.initials: KR
authors.lastname: Reddy
authors.forename: Abdus S
authors.initials: AS
authors.lastname: Wahed
authors.forename: Steven H
authors.initials: SH
authors.lastname: Belle
authors.forename: Nezam H
authors.initials: NH
authors.lastname: Afdhal
authors.forename: Victor J
authors.initials: VJ
authors.lastname: Navarro
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Meyers
authors.forename: Edward
authors.initials: E
authors.lastname: Doo
authors.forename: Michael W
authors.initials: MW
authors.lastname: Fried
mesh_terms: D000328:Adult; D019540:Area Under Curve; D005234:Fatty Liver / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D019698:Hepatitis C, Chronic / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012838:Silymarin / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D012838:Silymarin